Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 18 03:58PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.16 Insider Own0.50% Shs Outstand31.87M Perf Week-3.72%
Market Cap11.81M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float31.71M Perf Month-6.44%
Income11.39M PEG- EPS next Q- Inst Own13.80% Short Float1.55% Perf Quarter-3.87%
Sales35.52M P/S0.33 EPS this Y- Inst Trans-36.51% Short Ratio1.88 Perf Half Y-64.37%
Book/sh0.88 P/B0.42 EPS next Y- ROA11.22% Short Interest0.49M Perf Year-80.90%
Cash/sh0.51 P/C0.73 EPS next 5Y- ROE- 52W Range0.26 - 3.28 Perf YTD-74.62%
Dividend Est.- P/FCF- EPS past 5Y- ROI255.09% 52W High-88.70% Beta3.63
Dividend TTM- Quick Ratio0.78 Sales past 5Y163.47% Gross Margin39.59% 52W Low44.20% ATR (14)0.02
Dividend Ex-Date- Current Ratio0.96 EPS Y/Y TTM94.66% Oper. Margin-98.84% RSI (14)41.82 Volatility5.86% 5.77%
Employees53 Debt/Eq0.66 Sales Y/Y TTM-55.76% Profit Margin32.07% Recom1.00 Target Price40.00
Option/ShortNo / Yes LT Debt/Eq0.29 EPS Q/Q102.33% Payout0.00% Rel Volume0.31 Prev Close0.39
Sales Surprise- EPS Surprise- Sales Q/Q-90.21% EarningsApr 08 BMO Avg Volume261.10K Price0.37
SMA20-1.10% SMA50-11.75% SMA200-42.03% Trades Volume80,505 Change-4.97%
Date Action Analyst Rating Change Price Target Change
Aug-31-21Initiated Cantor Fitzgerald Overweight $22
May-18-21Initiated H.C. Wainwright Buy $23
Sep-11-20Initiated BTIG Research Buy
Jul-12-19Upgrade WBB Securities Buy → Strong Buy
Mar-12-19Upgrade WBB Securities Speculative Buy → Buy
Jan-26-18Initiated Nomura Buy $18
Oct-06-17Initiated Seaport Global Securities Buy $19
Oct-04-17Reiterated H.C. Wainwright Buy $33 → $36
Feb-24-17Reiterated FBR & Co. Outperform $36 → $25
Jul-27-16Reiterated FBR Capital Outperform $33 → $36
Jul-09-24 08:00AM
Jun-03-24 07:00AM
May-06-24 07:43AM
Apr-24-24 07:00AM
09:23AM Loading…
Apr-08-24 09:23AM
Apr-02-24 07:00AM
Mar-11-24 07:00AM
Mar-05-24 07:00AM
Feb-20-24 07:00AM
Jan-26-24 12:46PM
Jan-25-24 09:05AM
Dec-20-23 08:45AM
Dec-12-23 07:00AM
07:00AM Loading…
Dec-04-23 07:00AM
Dec-03-23 01:11PM
Nov-30-23 09:08AM
Nov-27-23 01:41PM
Nov-14-23 08:00AM
Oct-03-23 07:00AM
Sep-22-23 04:15PM
Sep-18-23 07:00AM
Sep-05-23 07:00AM
Aug-17-23 07:00AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jul-25-23 03:58PM
Jul-21-23 09:33AM
07:00AM Loading…
Jun-12-23 08:00AM
May-22-23 07:00AM
May-15-23 06:17PM
May-09-23 07:00AM
May-01-23 07:00AM
Apr-28-23 07:00AM
Apr-17-23 07:39AM
Apr-11-23 07:00AM
Apr-03-23 01:26PM
Mar-30-23 08:00AM
Mar-23-23 07:32AM
Mar-21-23 07:00AM
Mar-16-23 06:15PM
Mar-08-23 07:05PM
Feb-28-23 08:01AM
Feb-16-23 08:01AM
Feb-15-23 07:00AM
Feb-10-23 03:10PM
Feb-06-23 07:00AM
Jan-26-23 07:00AM
Jan-03-23 11:07AM
Dec-27-22 02:53PM
Dec-07-22 09:45AM
Dec-06-22 01:36PM
Dec-02-22 09:00AM
Dec-01-22 04:01PM
Nov-29-22 08:00AM
Nov-24-22 05:19AM
Nov-17-22 08:30AM
Nov-15-22 03:09PM
Nov-14-22 08:59AM
Nov-13-22 07:33AM
Nov-07-22 09:49AM
Nov-04-22 07:00AM
Oct-30-22 08:58AM
Oct-27-22 07:45AM
Oct-26-22 07:00AM
Oct-20-22 01:08PM
Oct-19-22 12:34PM
Oct-18-22 07:00AM
Oct-03-22 11:20AM
Aug-18-22 11:04AM
Aug-17-22 10:12AM
Aug-10-22 08:17AM
Jul-12-22 08:00AM
Jun-24-22 05:31AM
Jun-23-22 01:01PM
Jun-17-22 08:30AM
May-25-22 09:15AM
May-10-22 07:37AM
May-09-22 08:30AM
May-06-22 11:20AM
May-04-22 03:17PM
Apr-14-22 09:55AM
Apr-11-22 09:00AM
Mar-17-22 07:59AM
Mar-15-22 09:00AM
Mar-10-22 07:00AM
Mar-03-22 04:10AM
RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.